Breaking News — Eli Lilly has become the first pharmaceutical company to simultaneously top both the innovation and invention categories in a closely watched annual R&D performance ranking by consulting firm IDEA Pharma, marking a historic milestone in the industry.
The report, released early Tuesday, measures innovation based on revenue generated from newly approved drugs, while invention evaluates the number of drugs in development and the company's R&D investment. Lilly's dual leadership underscores its strategic focus on pipeline productivity and commercial execution.
“This is the first time we’ve seen one company lead in both metrics since we started the ranking over a decade ago,” said Dr. Jason Anderson, CEO of IDEA Pharma. “Eli Lilly’s performance reflects a rare alignment of scientific discovery and market success.”
Lilly’s stock rose modestly in premarket trading following the news, which comes amid a broader wave of positive sentiment for the drugmaker. The company has recently won approvals for obesity drug Zepbound and Alzheimer’s treatment donanemab, both of which contributed to its revenue surge.
Background
IDEA Pharma’s Pharmaceutical Innovation & Invention Index ranks the world’s largest drugmakers annually. The innovation score is derived from percentage of sales from drugs approved in the last five years. The invention score factors in pipeline density, R&D spending as a percentage of revenue, and number of late-stage candidates.
Previous top performers in innovation included Novartis and AstraZeneca, while invention leaders often shifted among Roche, Pfizer, and Merck. Lilly’s simultaneous ascent reflects a rare convergence: a deep pipeline and strong commercial uptake of new products.
Relay Therapeutics Shares Surge on Promising Phase 2 Data
In a separate development, Relay Therapeutics reported positive Phase 2 data for its drug zovegalisib in a group of rare diseases causing abnormal vasculature development. The results sent the company’s shares up 9% in premarket trading.
The data showed significant improvement in patients with PIK3CA-related overgrowth spectrum (PROS), a set of conditions with no approved therapies. “Zovegalisib has the potential to become a first-in-class treatment for these underserved patients,” said Dr. Leslie Holman, chief medical officer at Relay Therapeutics.
What This Means
The ranking reinforces Lilly’s position as a top-tier R&D performer at a time when the industry faces rising pressure on drug pricing and competition from biosimilars. Investors may view Lilly’s dual ranking as a signal of sustainable growth, potentially attracting more capital into its pipeline.
For the broader pharma sector, the IDEA Pharma index serves as a benchmarking tool. Companies that rank high in innovation often command premium valuations, while invention leaders are seen as future revenue drivers. Lilly’s unique achievement could spark increased R&D investment across the industry.
Relay’s positive data also highlights growing interest in precision medicines for rare genetic disorders. If zovegalisib gains approval, it could create a new market category and offer relief to thousands of patients worldwide.
This story was updated with additional analyst comments. Follow our live coverage of pharmaceutical earnings and regulatory decisions.